Halozyme Therapeutics
Open
$64.06
Prev. Close
$64.07
High
$64.06
Low
$64.06
Market Snapshot
$7.42B
23.4
3.50
$1.02B
423
The company is headquartered in San Diego, California and currently employs 423 full-time employees. The company went IPO on 2003-01-30.
Halozyme Therapeutics has appointed Darren Snellgrove as CFO, effective June 8, 2026, to strengthen its financial strategy and drive future growth initiatives.
The company is headquartered in San Diego, California and currently employs 423 full-time employees. The company went IPO on 2003-01-30.
Recently from Cashu
Halozyme Therapeutics Appoints David Ramsay as Interim CFO Amid Executive Search
Halozyme Therapeutics Appoints David Ramsay as Interim CFO Halozyme Therapeutics, Inc. announces the appointment of David Ramsay as Interim Chief Financial Officer (CFO), a decision that looks to bols…
Halozyme Therapeutics' Insider Sale Raises Questions About Leadership Confidence and Market Perception
Halozyme Therapeutics Signals Leadership Confidence Amid Insider Sale In a recent disclosure to the Securities and Exchange Commission (SEC), Cortney Caudill, the Senior Vice President of Halozyme The…
Insider Sale at Halozyme Raises Investor Questions Amid Innovative Partnership with WisdomTree
Halozyme Therapeutics: Bridging Innovation and Leadership Insight Amid Market Sensitivity Halozyme Therapeutics, a prominent player in the biopharmaceutical landscape, operates at the cutting edge of…
Blade Outboards Launches Halo Connect for Enhanced Electric Marine Propulsion Safety and Efficiency
Innovative Technology in Electric Marine Power: Blade Outboards Launches Halo Connect Platform Blade Outboards, committed to revolutionizing marine propulsion with electric technology, introduces the…